Appeals Court Nixes Savient Injunction Bid

Law360, New York (January 2, 2007, 12:00 AM EST) -- A federal appeals court has dealt a blow to Savient Pharmaceuticals Inc., opening the market for Savient’s $60 million weight control drug Oxandrin to generic competition.

On December 28, the U.S. Court of Appeals for the Federal Circuit denied Savient’s bid for a preliminary injunction, giving Sandoz Inc. and Upsher-Smith Laboratories Inc. the green light to launch generic oxandrolone products. Oxandralone is Oxandrin’s active ingredient.

Savient sued Sandoz and Upsher-Smith earlier this month in New Jersey for patent infringement, citing the defendants’ attempts to market generic...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.